We conducted a study to evaluate the sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) of five serologic tests. Subjects with negative or positive COVID-19 polymerase chain reaction (PRC) test results were tested with each of the serological tests. The results were compared with the reference PCR test. For the five tests evaluated, the Se ranged from 55.0% to 70.0% and the Sp ranged from 67.2% to 86.2%. PPV ranged from 53.2% to 80% and NPV from 75.0% to 86.2%. One test, the Wantai, had better specificity and sensitivity. None of the five tests had performance values of more than 90% in the entire sample. In symptomatic positive cases, the Wantai test reported excellent sensitivity. Overall, the low level of diagnostic performance of these tests does not support their use as an alternative to PCR for COVID-19 diagnostic. Test with better performance can be used for mass screening in low prevalence populations, to limit the indiscriminate use of PCR in context of resource-limited countries. Given the excellent sensitivity of Wantai in symptomatic cases, this test could be used as a referral test only in health facilities to discriminate suspected cases before PCR confirmation.
References
[1]
WHO (2020) COVID-19—Chronologie de l’action de l’OMS.
https://www.who.int/fr/news-room/detail/27-04-2020-who-timeline---covid-19
[2]
Zaki, A.M., Van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D. and Fouchier, R.A. (2012) Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. New England Journal of Medicine, 367, 1814-1820.
https://doi.org/10.1056/NEJMoa1211721
[3]
Kuiken, T., Fouchier, R.A., Schutten, M., Rimmelzwaan, G.F., Van Amerongen, G., van Riel, D., et al. (2003) Newly Discovered Coronavirus as the Primary Cause of Severe Acute Respiratory Syndrome. The Lancet, 362, 263-270.
https://doi.org/10.1016/S0140-6736(03)13967-0
[4]
WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/
[5]
Africa CDC—COVID-19 Daily Updates. https://africacdc.org/covid-19/
[6]
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
[7]
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X, Zhang, J., et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323, 1061-1069.
https://doi.org/10.1001/jama.2020.1585
[8]
Li, H., Liu, S.M., Yu, X.H., Tang, S.L. and Tang, C.K. (2020) Coronavirus Disease 2019 (COVID-19): Current Status and Future Perspectives. International Journal of Antimicrobial Agents, 55, Article ID: 105951.
https://doi.org/10.1016/j.ijantimicag.2020.105951
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139247/
[9]
Fourati, S., Audureau, E., Chevaliez, S. and Pawlotsky, J.M. (2020) Évaluation de la performance diagnostique des tests rapides d’orientation diagnostique antigéniques COVID-19. Laboratoire de virologie, département de prévention, diagnostic et traitement des Infections, INSERM U955 et Université Paris Paris-Est-Créteil.
https://fr.calameo.com/read/004021827da342e75785b?utm_source=platform&utm_medium=email&utm_campaign=book_created&utm_content=html&utm_term=4021827
[10]
Hardy, É.J.L. and Flori, P. (2021) Spécificités épidémiologiques de la COVID-19 en Afrique: Préoccupation de santé publique actuelle ou future? Annales Pharmaceutiques Françaises, 79, 216-226. https://doi.org/10.1016/j.pharma.2020.10.011
[11]
Ara, J., Islam, M.S., Kader, M.T.U., Das, A., Hasib, F.Y., Islam, M.S., et al. (2022) Sero-Prevalence of Anti-SARS-CoV-2 Antibodies in Chattogram Metropolitan Area, Bangladesh. MedRxiv. https://doi.org/10.1101/2022.02.09.22270717
[12]
Aryal, S., Pandit, S., Pokhrel, S., Chhusyabaga, M., Bista, P., Bhatt, M.P., et al. (2022) Anti-SARS-CoV-2 Antibody Screening in Healthcare Workers and Its Correlation with Clinical Presentation in Tertiary Care Hospital, Kathmandu, Nepal, from November 2020 to January 2021. Interdisciplinary Perspectives on Infectious Diseases, 2022, Article ID: 8515051. https://doi.org/10.1155/2022/8515051
[13]
Audu, R.A., Stafford, K.A., Steinhardt, L., Musa, Z.A., Iriemenam, N., Ilori, E., et al. (2022) Seroprevalence of SARS-CoV-2 in Four States of Nigeria in October 2020: A Population-Based Household Survey. PLOS Global Public Health, 2, e0000363.
https://doi.org/10.1371/journal.pgph.0000363
[14]
Beaumont, A., Durand, C., Ledrans, M., Schwoebel, V., Noel, H., Diulius, D., et al. (2021) Séroprévalence des anticorps anti-SARS-CoV-2 après la première vague épidémique au sein d’une population vulnérable. Infectious Diseases Now, 51, S17-S18. https://doi.org/10.1016/j.idnow.2021.06.010
[15]
Konu, Y.R., Condé, S., Gbeasor-Komlanvi, F.A., Sadio, A.J., Tchankoni, M.K, Anani, J., et al. (2022) SARS-CoV-2 Antibody Seroprevalence in Togo, May-June 2021: A Cross-Sectional, Nationally Representative, Age-Stratified Serosurvey.
https://doi.org/10.21203/rs.3.rs-1769582/v1
[16]
Lewin, A., De Serres, G., Grégoire, Y., Perreault, J., Drouin, M., Fournier, M.J., et al. (2022) Seroprevalence of SARS-CoV-2 Antibodies among Blood Donors in Québec: An Update from a Serial Cross-Sectional Study. Canadian Journal of Public Health, 113, 385-393. https://doi.org/10.17269/s41997-022-00622-y
[17]
Zoukal, S., Nani, S. and Hassoune, S. (2020) Place des tests antigeniques et serologiques dans le diagnostic de l’infection a covid19: Revue systematique. Revue Marocaine de Santé Publique, 7, 10-17.
https://revues.imist.ma/index.php/RMSP/article/view/20958
[18]
Kassaï, B., Manière, J. and Nguyen, K.A. (2006) Qu’attendre d’un «test diagnostique» Les indices de précision des tests diagnostiques (1re partie). Médecine, 2, 368-371.
[19]
Kassaï, B., Manière, J. and Nguyen, K.A. (2006) Qu’attendre d’un «test diagnostique» (2e partie) L’évaluation des tests diagnostiques. Médecine, 2, 416-418.
[20]
Batchi-Bouyou, A.L., Ingoba, L.L., Ndounga, M., Vouvoungui, J.C., Mapanguy, C.C.M., Boumpoutou, K.R., et al. (2021) High SARS-CoV-2 IgG/IGM Seroprevalence in Asymptomatic Congolese in Brazzaville, the Republic of Congo. International Journal of Infectious Diseases, 106, 3-7.
https://doi.org/10.1016/j.ijid.2020.12.065
[21]
Ingoba, L.L., Djontu, J.C., Mapanguy, C.C.M., Mouzinga, F., Kietela, S.D., Vouvoungui, C., et al. (2022) Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Population Living in Bomassa Village, Republic of Congo. IJID Regions, 2, 130-136.
https://doi.org/10.1016/j.ijregi.2022.01.002
To, K.K.W., Tsang, O.T.Y., Chik-Yan Yip, C., Chan, K.H., Wu, T.C., Chan, J.M.C., et al. (2020) Consistent Detection of 2019 Novel Coronavirus in Saliva. Clinical Infectious Diseases, 71, 841-843. https://doi.org/10.1093/cid/ciaa149
[24]
Connelly, L.M. (2008) Pilot Studies. Medsurg Nursing, 17, 411-412.
https://doi.org/10.12968/bjon.2008.17.7.29056
[25]
Caël, B. and Lepiller, Q. (2021). Le virus SARS-Cov-2 a muté: quel impact sur l'efficacité des tests serologiques?
https://www.univadis.fr/viewarticle/e50cbc69-4051-3fd7-b483-dfcd40b99085?uuid=e50cbc69-4051-3fd7-b483-dfcd40b99085
